TransMedics Group shares rose after the FDA granted conditional approval for a clinical trial of its Next-Generation OCS ENHANCE Heart system, designed to improve organ preservation for transplants.

#TMDX #TMDXStock #TMDXNews #TMDXStockNews #TransMedics #TransMedicsStock #TransMedicsNews

TransMedics CEO Waleed Hassanein emphasized long-term growth, stating, “We are already ramping up our investments to drive the next several waves of growth that will deliver substantially more top and bottom line growth.”

#TMDX #TransMedics #TMDXStock #TMDXNews #TMDXStockNews
$TMDX